

# CITATION REPORT

List of articles citing

Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer

DOI: 10.1046/j.1464-410x.2000.00432.x  
BJU International, 2000, 85, 276-80.

**Source:** <https://exaly.com/paper-pdf/31325593/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
48	Vascular endothelial growth factor in prostate cancer. <i>Urology</i> , <b>2000</b> , 56, 183	1.6	5
47	Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>2001</b> , 35, 437-52		56
46	Clinical implications of circulating angiogenic factors in cancer patients. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1207-25	2.2	491
45	Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. <i>American Journal of Clinical Pathology</i> , <b>2001</b> , 116, 115-21	1.9	66
44	Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 1737-42	5.6	81
43	Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. <i>American Journal of Pathology</i> , <b>2002</b> , 160, 413-8	5.8	126
42	Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. <i>Lung Cancer</i> , <b>2002</b> , 35, 29-34	5.9	64
41	Growth factors and their receptors in prostate cancer. <i>BJU International</i> , <b>2002</b> , 89, 230-40	5.6	24
40	Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients. <i>Prostate</i> , <b>2002</b> , 51, 84-97	4.2	37
39	Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. <i>Prostate</i> , <b>2002</b> , 51, 268-75	4.2	136
38	Transrectal colour Doppler ultrasonography for quantifying angiogenesis in prostate cancer. <i>BJU International</i> , <b>2003</b> , 91, 223-6	5.6	15
37	Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. <i>BJU International</i> , <b>2003</b> , 91, 716-20	5.6	73
36	Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. <i>Urology</i> , <b>2003</b> , 61, 765-9	1.6	23
35	Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. <i>Urology</i> , <b>2003</b> , 62, 374-7	1.6	96
34	Molecular pathway for cancer metastasis to bone. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 39044-50	5.4	114
33	Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 1250-5	11.5	68
32	Role of coagulation and fibrinolytic system in prostate cancer. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2003</b> , 29, 301-8	5.3	25

31	Metastatic properties of prostate cancer cells are controlled by VEGF. <i>Cell Communication and Adhesion</i> , <b>2004</b> , 11, 1-11		53
30	Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1655-63	2.2	102
29	Smart drugs in prostate cancer. <i>European Urology</i> , <b>2004</b> , 45, 1-17	10.2	27
28	[Markers in patients with squamous cell carcinoma of the oral cavity. Expression and long-term follow-up of VEGF, FLT-1 and Tie2 in serum]. <i>Hno</i> , <b>2004</b> , 52, 235-41	3.7	1
27	Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. <i>Urology</i> , <b>2004</b> , 63, 327-32	1.6	25
26	Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD. <i>Journal of Cellular Biochemistry</i> , <b>2004</b> , 91, 66-75	2.8	
25	Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. <i>Prostate</i> , <b>2005</b> , 64, 303-15	4.2	37
24	Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. <i>Current Cancer Drug Targets</i> , <b>2005</b> , 5, 307-23	2.8	38
23	Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 1557-61	4	15
22	Mast Cells. <b>2005</b> ,		3
21	Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. <i>Clinical Genitourinary Cancer</i> , <b>2006</b> , 4, 269-74	3.3	33
20	Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. <i>Clinics</i> , <b>2006</b> , 61, 401-8	2.3	30
19	Immunohistological detection of growth factors and cytokines in tissue mast cells. <i>Methods in Molecular Biology</i> , <b>2006</b> , 315, 257-72	1.4	4
18	Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. <i>British Journal of Cancer</i> , <b>2007</b> , 97, 978-85	8.7	197
17	The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. <i>BJU International</i> , <b>2007</b> , 99, 1150-3	5.6	26
16	Post-collection, pre-measurement variables affecting VEGF levels in urine biospecimens. <i>Journal of Cellular and Molecular Medicine</i> , <b>2008</b> , 12, 343-50	5.6	13
15	The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. <i>Carcinogenesis</i> , <b>2008</b> , 29, 1077-82	4.6	35
14	Cytokines as potential tumour markers. <i>Expert Opinion on Medical Diagnostics</i> , <b>2008</b> , 2, 691-711		12

13	Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. <i>Cancer Prevention Research</i> , <b>2009</b> , 2, 673-82	3.2	184
12	The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. <i>Biochemical Pharmacology</i> , <b>2009</b> , 77, 1151-60	6	40
11	Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line. <i>Cancer Letters</i> , <b>2009</b> , 276, 14-20	9.9	37
10	VEGF and prostatic cancer: a systematic review. <i>European Journal of Cancer Prevention</i> , <b>2010</b> , 19, 385-92	2	33
9	Effects of adipocytes on the proliferation and differentiation of prostate cancer cells in a 3-D culture model. <i>International Journal of Urology</i> , <b>2010</b> , 17, 369-76	2.3	24
8	Vascular endothelial growth factor (VEGF) and prostate pathology. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2010</b> , 36, 430-7; discussion 438	2	5
7	New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. <i>Nutrition and Cancer</i> , <b>2012</b> , 64, 4-22	2.8	52
6	An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. <i>Journal of Men's Health</i> , <b>2012</b> , 9, 182-189	1.2	1
5	Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. <i>Prostate</i> , <b>2012</b> , 72, 705-12	4.2	31
4	Association of the serum vascular endothelial growth factor levels with benign prostate hyperplasia and prostate malignancies. <i>Nephro-Urology Monthly</i> , <b>2014</b> , 6, e14778	0.4	7
3	Phase I/II study evaluating the safety and clinical efficacy of tamsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 331-337	4.3	11
2	Combined Dynamic Alterations in Urinary VEGF Levels and Tissue ADAM9 Expression as Markers for Lethal Phenotypic Progression of Prostate Cancer. <i>Chinese Journal of Physiology</i> , <b>2012</b> , 55, 390-7	1.6	6
1	The Effects of Isoflavone Supplementation on Serum PSA, Lipid Profile, Antioxidant and Immune System in Prostate Cancer Patients. <i>Journal of the Korean Society of Food Science and Nutrition</i> , <b>2004</b> , 33, 1294-1301	1.5	